Abstract
Background: While our previous research has demonstrated that the NLRP3 inflammasome is involved in epilepsy progression, the effects of the specific NLRP3 inhibitor CY-09 remain poorly understood. Therefore, the aim of the present study was to investigate the efficacy of CY-09 against pentylenetetrazole (PTZ)-induced neuronal loss in mice.
Methods: The expressions of the proinflammatory factors interleukin-1β and interleukin-18 were examined by western blot and enzyme-linked immunosorbent assays. Western blot analysis was applied to detect the level of astrocyte activation. Neuronal apoptosis was determined by western blot analysis combined with immunostaining specific for neuronal nuclei.
Results: We found that CY-09 ameliorated the progression of the kindling process and inhibited PTZ-induced neuronal loss by attenuating the activation of astrocytes and the secretion of NLRP3- dependent neuroinflammation.
Conclumsion: These findings indicate that CY-09 may represent an important treatment agent for epilepsy and other NLRP3 inflammasome-associated diseases.
Keywords: Epilepsy, NLRP3 inflammasome, CY-09, inflammation, apoptosis, neuron.
Graphical Abstract
Current Molecular Pharmacology
Title:Molecular Mechanism of a Specific NLRP3 Inhibitor to Alleviate Seizure Severity Induced by Pentylenetetrazole
Volume: 14
Author(s): Kai Shen, Wanzhi Jiang, Chunyan Zhang, Liangliang Cai, Qin Wang, Haiyan Yu, Zhiyuan Tang, Zhifeng Gu*Bohua Chen*
Affiliation:
- Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong,China
- Department of Pharmacy, Affiliated Hospital of Nantong University, Nantong,China
Keywords: Epilepsy, NLRP3 inflammasome, CY-09, inflammation, apoptosis, neuron.
Abstract:
Background: While our previous research has demonstrated that the NLRP3 inflammasome is involved in epilepsy progression, the effects of the specific NLRP3 inhibitor CY-09 remain poorly understood. Therefore, the aim of the present study was to investigate the efficacy of CY-09 against pentylenetetrazole (PTZ)-induced neuronal loss in mice.
Methods: The expressions of the proinflammatory factors interleukin-1β and interleukin-18 were examined by western blot and enzyme-linked immunosorbent assays. Western blot analysis was applied to detect the level of astrocyte activation. Neuronal apoptosis was determined by western blot analysis combined with immunostaining specific for neuronal nuclei.
Results: We found that CY-09 ameliorated the progression of the kindling process and inhibited PTZ-induced neuronal loss by attenuating the activation of astrocytes and the secretion of NLRP3- dependent neuroinflammation.
Conclumsion: These findings indicate that CY-09 may represent an important treatment agent for epilepsy and other NLRP3 inflammasome-associated diseases.
Export Options
About this article
Cite this article as:
Shen Kai , Jiang Wanzhi , Zhang Chunyan , Cai Liangliang , Wang Qin , Yu Haiyan , Tang Zhiyuan , Gu Zhifeng*, Chen Bohua *, Molecular Mechanism of a Specific NLRP3 Inhibitor to Alleviate Seizure Severity Induced by Pentylenetetrazole, Current Molecular Pharmacology 2021; 14 (4) . https://dx.doi.org/10.2174/1874467213666200810140749
DOI https://dx.doi.org/10.2174/1874467213666200810140749 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy
Current Neurovascular Research BDZs, Designer BDZs and Z-drugs: Pharmacology and Misuse Insights
Current Pharmaceutical Design Neurological Complications of Anderson-Fabry Disease
Current Pharmaceutical Design Editorial (Thematic Issue: Myokines and Exercise Training: More Shadows than Lights)
Current Pharmaceutical Design The Novel Antipsychotic Drug Cariprazine and Cognition Enhancing Drugs: Indications for their Use as the Add-on Therapy in Schizophrenia
Current Pharmaceutical Design Medications Acting on the GABA System in the Treatment of Alcoholic Patients
Current Pharmaceutical Design In Search of Novel and Therapeutically Significant Melatoninergic Ligands
Recent Patents on CNS Drug Discovery (Discontinued) Cognitive Impairment and Mossy Fiber Sprouting in a Rat Model of Drug-resistant Epilepsy Induced by Lithium-pilocarpine
Current Neurovascular Research Stopping Drug Therapy in Epilepsy
Current Pharmaceutical Design Neuromodulation of Hippocampal Synaptic Plasticity, Learning, and Memory by Noradrenaline
Central Nervous System Agents in Medicinal Chemistry Chemistry and Biology of Cyperus scariosus: An Overview
Current Chemical Biology Synthesis and Evaluation of the Anticonvulsant Activities of New 5-substitued-[1,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one Derivatives
Letters in Drug Design & Discovery ABC Multidrug Transporters: Target for Modulation of Drug Pharmacokinetics and Drug-Drug Interactions
Current Drug Targets The Role of mGlu Receptors in Hippocampal Plasticity Deficits in Neurological and Psychiatric Disorders: Implications for Allosteric Modulators as Novel Therapeutic Strategies
Current Neuropharmacology Changes in Psychiatric Diagnoses During the Transition Phase from Childhood to Adulthood in a Group of Patients with Intellectual Disability
Adolescent Psychiatry Phentermine and Topiramate Extended-Release for the Obesity: New Kids on the Block
Recent Patents on Cardiovascular Drug Discovery Social Behavior as an Endophenotype for Psychiatric Disorders Development of Mouse Models
Current Genomics Application of MicroPET in Basic Epilepsy Research
Current Medical Imaging Inhibition of Monoamine Neurotransmitter Transporters andCentral Nervous System Stimulation Induced by Synthetic Local Anesthetics and Cocaine: A Comparative Review
Current Medicinal Chemistry - Central Nervous System Agents High-Throughput Screening of Neuronal Cl- Channels: Why and How?
Current Neuropharmacology